We have characterised three new mutations in the uroporphyrinogen decarboxylase gene in familial porphyria cutanea tarda. The first of these was a G to A substitution in the 5' splice junction of exon 4 which generated an mRNA that lacked exon 4. The second was a nonsense mutation in exon 5 which changed the arginine residue at position 142 to a stop codon, and the third mutation, also in exon 5, was a triple base substitution from nucleotide position 417 to 419. This mutation encompassed two codons but only changed the amino acid predicted from the second codon, resulting in the replacement of valine with glutamine at position 134. This missense mutation has been described previously by Meguro et al. 1994, on one allele in a compound heterozygote with hepatoerythropoietic porphyria. This is the third case of an hepatoerythropoietic porphyria mutation in an individual diagnosed with familial porphyria cutanea tarda.

Download full-text PDF

Source
http://dx.doi.org/10.1002/(SICI)1098-1004(1999)13:5<412::AID-HUMU13>3.0.CO;2-NDOI Listing

Publication Analysis

Top Keywords

familial porphyria
12
porphyria cutanea
12
cutanea tarda
12
three mutations
8
mutations uroporphyrinogen
8
uroporphyrinogen decarboxylase
8
decarboxylase gene
8
gene familial
8
mutation exon
8
hepatoerythropoietic porphyria
8

Similar Publications

Porphyria is a rare and often underdiagnosed metabolic disorder that leads to abdominal pain, pelvic pain, changes in neurological states, and digestive issues due to a buildup of porphyrins in the body. Diagnosis can be especially difficult in young women, where symptoms of porphyria often overlap with gynecological conditions. We present a case of a 37-year-old female patient who was experiencing persistent lower abdominal and pelvic pain, brain fog and confusion, and a rash after long sun exposure.

View Article and Find Full Text PDF

The acute hepatic porphyrias (AHPs) are a family of rare genetic diseases associated with attacks of abdominal pain, vomiting, weakness, neuropathy, and other neurovisceral symptoms. Pathogenic variants in 1 of 4 enzymes of heme synthesis are necessary for the development of AHP, and the onset of acute attacks also requires the induction of δ-aminolevulinic acid synthase 1 (ALAS1), the first and rate-limiting step of heme synthesis in the liver. Givosiran is an RNA interference medication that inhibits hepatic ALAS1 and was designed to treat AHP.

View Article and Find Full Text PDF

Palliative Care Aspects of Acute Intermittent Porphyria - A Case Report.

Indian J Palliat Care

August 2024

Department of Onco-Anaesthesia and Palliative Medicine, All India Institute of Medical Sciences, Dr B.R. Ambedkar, Institute Rotary Cancer Hospital, New Delhi, Delhi, India.

Acute intermitttent porphyria belongs to a rare group of diseases hallmarked by deficient biosynthesis of heme. It carries a significant symptom burden, both physical and emotional,and therefore palliative care has emerged as an essential tool in the armamentarium of porphyria management . It takes care of the patient as a whole and caters to all aspects that the disease process demands.

View Article and Find Full Text PDF

Acute intermittent porphyria (AIP) is a rare autosomal dominant disorder characterized by defective porphyrin metabolism in the blood. It manifests through variable clinical features, among these are abdominal pain, nausea, vomiting, peripheral neuropathy, and seizure. The diverse presentation of AIP poses substantial diagnostic challenges due to its potential to mimic other medical conditions, delaying early recognition and intervention.

View Article and Find Full Text PDF

Effectiveness and tolerability of givosiran for the management of acute hepatic porphyria: A monocenter real-life evaluation.

Mol Genet Metab Rep

September 2024

Scientific Institut for Research and Health Care, Fondazione Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, Italy.

Article Synopsis
  • Acute hepatic porphyrias (AHPs) are rare genetic disorders that affect heme production, and new therapies are being developed to treat them.
  • Givosiran, an RNA interference treatment, has been approved for AHP patients over 12 years old after successful phase III trials.
  • A recent case series from Italy shows that givosiran is well-tolerated in the long term and reduces attack frequency, while also improving patients' quality of life, pain, and fatigue.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!